Loading…

Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety

To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subj...

Full description

Saved in:
Bibliographic Details
Published in:Alcohol and alcoholism (Oxford) 2014-11, Vol.49 (6), p.654-660
Main Authors: MORLEY, K. C, BAILLIE, A, LEUNG, S, ADDOLORATO, G, LEGGIO, L, HABER, P. S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3
cites cdi_FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3
container_end_page 660
container_issue 6
container_start_page 654
container_title Alcohol and alcoholism (Oxford)
container_volume 49
creator MORLEY, K. C
BAILLIE, A
LEUNG, S
ADDOLORATO, G
LEGGIO, L
HABER, P. S
description To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence that seeks to improve motivation for change, enhance strategies to prevent relapse and encourage compliance with treatment. Intention-to-treat analyses revealed that alcohol consumption (heavy drinking days, drinks per drinking day) significantly reduced across all three groups during the treatment period. There were no statistically significant advantages to treatment on time to first heavy drinking day (relapse) (P = 0.08), nor time to first drink (lapse) (P = 0.18). A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0.05). There was also a beneficial effect for baclofen 60 mg/day relative to placebo on time to relapse in this comorbid group (P < 0.05). Both doses of baclofen were well tolerated. There were no serious adverse events. In spite of the small sample for a 3-arm clinical trial, this study suggests a specific role of baclofen in alcohol-dependent individuals with comorbid anxiety. Replication in larger, fully-powered studies is required.
doi_str_mv 10.1093/alcalc/agu062
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4804107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25246489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3</originalsourceid><addsrcrecordid>eNpVkM1LwzAUwIMobk6PXiUXj3VJk7bpRZjzEwaKTK8hTV62SpeMtBP33xvp_IKQd3i_9_VD6JSSC0pKNlaNjm-sFhuSp3toSHnOE5aRdB8NScGyhHDKB-iobd8IoZyl9BAN0iyNmCiH6PVK6cZbcNj6gLsl4HkA1a3AddhbPGm0X_oGX8ManAGnAStn8JNv27pqAD_7-EVu6lc-VLXBE_dRQ7c9RgdWNS2c7OIIvdzezKf3yezx7mE6mSWa06JL4hKQE8UsJ1wwIUqIkQqbljYzBSWmgrzKLNFFzonmRlUVL4zN0oIwUxDLRuiy77veVCswOq4dVCPXoV6psJVe1fJ_xtVLufDvkovoJfoZoaRvoEO8KYD9qaVEfgmWvWDZC4782d-BP_S30Qic7wDVxkIblNN1-8sJIRgvS_YJsV6Gqw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>MORLEY, K. C ; BAILLIE, A ; LEUNG, S ; ADDOLORATO, G ; LEGGIO, L ; HABER, P. S</creator><creatorcontrib>MORLEY, K. C ; BAILLIE, A ; LEUNG, S ; ADDOLORATO, G ; LEGGIO, L ; HABER, P. S</creatorcontrib><description>To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence that seeks to improve motivation for change, enhance strategies to prevent relapse and encourage compliance with treatment. Intention-to-treat analyses revealed that alcohol consumption (heavy drinking days, drinks per drinking day) significantly reduced across all three groups during the treatment period. There were no statistically significant advantages to treatment on time to first heavy drinking day (relapse) (P = 0.08), nor time to first drink (lapse) (P = 0.18). A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P &lt; 0.05). There was also a beneficial effect for baclofen 60 mg/day relative to placebo on time to relapse in this comorbid group (P &lt; 0.05). Both doses of baclofen were well tolerated. There were no serious adverse events. In spite of the small sample for a 3-arm clinical trial, this study suggests a specific role of baclofen in alcohol-dependent individuals with comorbid anxiety. Replication in larger, fully-powered studies is required.</description><identifier>ISSN: 0735-0414</identifier><identifier>EISSN: 1464-3502</identifier><identifier>DOI: 10.1093/alcalc/agu062</identifier><identifier>PMID: 25246489</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Addictive behaviors ; Adult ; Adult and adolescent clinical studies ; Alcohol Abstinence - statistics &amp; numerical data ; Alcoholism ; Alcoholism - complications ; Alcoholism - drug therapy ; Alcoholism - psychology ; Alcoholism and acute alcohol poisoning ; Anxiety - complications ; Anxiety - psychology ; Baclofen - therapeutic use ; Biological and medical sciences ; Double-Blind Method ; Female ; GABA-B Receptor Agonists - therapeutic use ; Humans ; Male ; Medical sciences ; Middle Aged ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Recurrence ; Toxicology ; Treatment ; Treatment Outcome</subject><ispartof>Alcohol and alcoholism (Oxford), 2014-11, Vol.49 (6), p.654-660</ispartof><rights>2015 INIST-CNRS</rights><rights>The Author 2014. Medical Council on Alcohol and Oxford University Press. All rights reserved.</rights><rights>The Author 2014. Medical Council on Alcohol and Oxford University Press. All rights reserved 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3</citedby><cites>FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28883499$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25246489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MORLEY, K. C</creatorcontrib><creatorcontrib>BAILLIE, A</creatorcontrib><creatorcontrib>LEUNG, S</creatorcontrib><creatorcontrib>ADDOLORATO, G</creatorcontrib><creatorcontrib>LEGGIO, L</creatorcontrib><creatorcontrib>HABER, P. S</creatorcontrib><title>Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety</title><title>Alcohol and alcoholism (Oxford)</title><addtitle>Alcohol Alcohol</addtitle><description>To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence that seeks to improve motivation for change, enhance strategies to prevent relapse and encourage compliance with treatment. Intention-to-treat analyses revealed that alcohol consumption (heavy drinking days, drinks per drinking day) significantly reduced across all three groups during the treatment period. There were no statistically significant advantages to treatment on time to first heavy drinking day (relapse) (P = 0.08), nor time to first drink (lapse) (P = 0.18). A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P &lt; 0.05). There was also a beneficial effect for baclofen 60 mg/day relative to placebo on time to relapse in this comorbid group (P &lt; 0.05). Both doses of baclofen were well tolerated. There were no serious adverse events. In spite of the small sample for a 3-arm clinical trial, this study suggests a specific role of baclofen in alcohol-dependent individuals with comorbid anxiety. Replication in larger, fully-powered studies is required.</description><subject>Addictive behaviors</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Alcohol Abstinence - statistics &amp; numerical data</subject><subject>Alcoholism</subject><subject>Alcoholism - complications</subject><subject>Alcoholism - drug therapy</subject><subject>Alcoholism - psychology</subject><subject>Alcoholism and acute alcohol poisoning</subject><subject>Anxiety - complications</subject><subject>Anxiety - psychology</subject><subject>Baclofen - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>GABA-B Receptor Agonists - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Recurrence</subject><subject>Toxicology</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><issn>0735-0414</issn><issn>1464-3502</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpVkM1LwzAUwIMobk6PXiUXj3VJk7bpRZjzEwaKTK8hTV62SpeMtBP33xvp_IKQd3i_9_VD6JSSC0pKNlaNjm-sFhuSp3toSHnOE5aRdB8NScGyhHDKB-iobd8IoZyl9BAN0iyNmCiH6PVK6cZbcNj6gLsl4HkA1a3AddhbPGm0X_oGX8ManAGnAStn8JNv27pqAD_7-EVu6lc-VLXBE_dRQ7c9RgdWNS2c7OIIvdzezKf3yezx7mE6mSWa06JL4hKQE8UsJ1wwIUqIkQqbljYzBSWmgrzKLNFFzonmRlUVL4zN0oIwUxDLRuiy77veVCswOq4dVCPXoV6psJVe1fJ_xtVLufDvkovoJfoZoaRvoEO8KYD9qaVEfgmWvWDZC4782d-BP_S30Qic7wDVxkIblNN1-8sJIRgvS_YJsV6Gqw</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>MORLEY, K. C</creator><creator>BAILLIE, A</creator><creator>LEUNG, S</creator><creator>ADDOLORATO, G</creator><creator>LEGGIO, L</creator><creator>HABER, P. S</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20141101</creationdate><title>Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety</title><author>MORLEY, K. C ; BAILLIE, A ; LEUNG, S ; ADDOLORATO, G ; LEGGIO, L ; HABER, P. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Addictive behaviors</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Alcohol Abstinence - statistics &amp; numerical data</topic><topic>Alcoholism</topic><topic>Alcoholism - complications</topic><topic>Alcoholism - drug therapy</topic><topic>Alcoholism - psychology</topic><topic>Alcoholism and acute alcohol poisoning</topic><topic>Anxiety - complications</topic><topic>Anxiety - psychology</topic><topic>Baclofen - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>GABA-B Receptor Agonists - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Recurrence</topic><topic>Toxicology</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MORLEY, K. C</creatorcontrib><creatorcontrib>BAILLIE, A</creatorcontrib><creatorcontrib>LEUNG, S</creatorcontrib><creatorcontrib>ADDOLORATO, G</creatorcontrib><creatorcontrib>LEGGIO, L</creatorcontrib><creatorcontrib>HABER, P. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alcohol and alcoholism (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MORLEY, K. C</au><au>BAILLIE, A</au><au>LEUNG, S</au><au>ADDOLORATO, G</au><au>LEGGIO, L</au><au>HABER, P. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety</atitle><jtitle>Alcohol and alcoholism (Oxford)</jtitle><addtitle>Alcohol Alcohol</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>49</volume><issue>6</issue><spage>654</spage><epage>660</epage><pages>654-660</pages><issn>0735-0414</issn><eissn>1464-3502</eissn><abstract>To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence that seeks to improve motivation for change, enhance strategies to prevent relapse and encourage compliance with treatment. Intention-to-treat analyses revealed that alcohol consumption (heavy drinking days, drinks per drinking day) significantly reduced across all three groups during the treatment period. There were no statistically significant advantages to treatment on time to first heavy drinking day (relapse) (P = 0.08), nor time to first drink (lapse) (P = 0.18). A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P &lt; 0.05). There was also a beneficial effect for baclofen 60 mg/day relative to placebo on time to relapse in this comorbid group (P &lt; 0.05). Both doses of baclofen were well tolerated. There were no serious adverse events. In spite of the small sample for a 3-arm clinical trial, this study suggests a specific role of baclofen in alcohol-dependent individuals with comorbid anxiety. Replication in larger, fully-powered studies is required.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>25246489</pmid><doi>10.1093/alcalc/agu062</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-0414
ispartof Alcohol and alcoholism (Oxford), 2014-11, Vol.49 (6), p.654-660
issn 0735-0414
1464-3502
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4804107
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
subjects Addictive behaviors
Adult
Adult and adolescent clinical studies
Alcohol Abstinence - statistics & numerical data
Alcoholism
Alcoholism - complications
Alcoholism - drug therapy
Alcoholism - psychology
Alcoholism and acute alcohol poisoning
Anxiety - complications
Anxiety - psychology
Baclofen - therapeutic use
Biological and medical sciences
Double-Blind Method
Female
GABA-B Receptor Agonists - therapeutic use
Humans
Male
Medical sciences
Middle Aged
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Recurrence
Toxicology
Treatment
Treatment Outcome
title Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A01%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baclofen%20for%20the%20Treatment%20of%20Alcohol%20Dependence%20and%20Possible%20Role%20of%20Comorbid%20Anxiety&rft.jtitle=Alcohol%20and%20alcoholism%20(Oxford)&rft.au=MORLEY,%20K.%20C&rft.date=2014-11-01&rft.volume=49&rft.issue=6&rft.spage=654&rft.epage=660&rft.pages=654-660&rft.issn=0735-0414&rft.eissn=1464-3502&rft_id=info:doi/10.1093/alcalc/agu062&rft_dat=%3Cpubmed_cross%3E25246489%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-464e60a3f40483889e04818f29f5d710dbe6b5f0c7640c4dabb47df52703d70f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/25246489&rfr_iscdi=true